JUNS
Jupiter Neurosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.28
+0.61%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 64.7K | 21.8K | — | — | 233.3K |
| Cost of Revenue | 7.5K | 4.2K | — | — | — |
| Gross Profit | 57.1K | 17.6K | — | — | 233.3K |
| Operating Expenses | |||||
| R&D Expense | (214.8K) | 2.1M | 492.7K | 954.8K | 942.8K |
| SG&A Expense | 8.0M | 6.8M | 2.6M | 2.9M | 2.7M |
| General & Admin Expense | 8.0M | 6.8M | 2.6M | 2.9M | 2.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.1M | — | — | — | — |
| Total Operating Expenses | 9.9M | 8.9M | 3.1M | 3.9M | 3.7M |
| Cost and Expenses | 9.9M | 8.9M | 3.1M | 3.9M | 3.7M |
| Operating Income (EBIT) | (9.8M) | (8.9M) | (3.1M) | (3.9M) | (3.4M) |
| Non-Operating | |||||
| Interest Income | 5.1K | — | 5.6K | 482.00 | 617.00 |
| Interest Expense | 206.9K | 66.0K | 248.4K | 218.7K | 740.9K |
| Net Interest Income | (201.8K) | (66.0K) | (242.8K) | (218.2K) | (740.2K) |
| Other Non-Op Income/Expense | 612.4K | 263.8K | 651.7K | (912.9K) | (1.5M) |
| Non-Operating Income (excl Interest) | (326.1K) | (329.8K) | (900.0K) | 694.2K | 784.3K |
| EBT (Pre-Tax Income) | (9.2M) | (8.6M) | (2.4M) | (4.8M) | (5.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (9.2M) | (8.6M) | (2.4M) | (4.8M) | (5.0M) |
| Earnings from Cont. Ops | (9.2M) | (8.6M) | (2.4M) | (4.8M) | (5.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (9.2M) | (8.6M) | (2.4M) | (4.8M) | (5.0M) |
| Per Share | |||||
| Basic EPS | ($19.33) | ($18.75) | ($6.36) | ($10.50) | ($11.25) |
| Diluted EPS | ($19.33) | ($18.75) | ($6.36) | ($10.50) | ($11.25) |
| Revenue Per Share | $0.12 | $0.05 | $0.00 | $0.00 | $0.53 |
| Shares | |||||
| Basic Shares Outstanding | 557567 | 461715 | 383774 | 438352 | 438352 |
| Diluted Shares Outstanding | 557567 | 461715 | 383774 | 438352 | 438352 |
| Profitability Metrics | |||||
| EBITDA | (9.5M) | (8.6M) | (2.2M) | (4.6M) | (4.2M) |
| D&A | — | — | — | — | — |
| EBIT | (9.5M) | (8.6M) | (2.2M) | (4.6M) | (4.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026